These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R; Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554 [TBL] [Abstract][Full Text] [Related]
25. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525 [TBL] [Abstract][Full Text] [Related]
26. HIV and refractory anemia with excess blasts (RAEB). Modest GA; Cooley TP; Zacks JF Am J Hematol; 2002 Aug; 70(4):318-9. PubMed ID: 12210814 [TBL] [Abstract][Full Text] [Related]
27. Treatment of myelodysplastic syndrome with cyclosporin A. Chen S; Jiang B; Da W; Gong M; Guan M Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496 [TBL] [Abstract][Full Text] [Related]
28. [Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome]. Fernández-Sojo J; Vives S; Oliveras Vilà T; Ribera JM Med Clin (Barc); 2014 Jul; 143(1):43-4. PubMed ID: 24183124 [No Abstract] [Full Text] [Related]
29. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients]. Shao XR; Liang H; Guan XJ Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920 [No Abstract] [Full Text] [Related]
30. Decitabine (Dacogen) for myelodysplastic syndromes. Med Lett Drugs Ther; 2006 Nov; 48(1247):91-2. PubMed ID: 17082739 [No Abstract] [Full Text] [Related]
31. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. Gidwani R; Khan ZM; Fenaux P; Beach CL; Pashos CL J Med Econ; 2012; 15(1):145-54. PubMed ID: 21988635 [TBL] [Abstract][Full Text] [Related]
32. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781 [TBL] [Abstract][Full Text] [Related]
34. [Clinical, hematologic and developmental characteristics of myelodysplastic syndromes. Study of a group of patients with a long-term follow-up]. Di Giovanni S; Giallonardo P; Costa MP; Carducci P Recenti Prog Med; 1987 Feb; 78(2):63-8. PubMed ID: 3473582 [No Abstract] [Full Text] [Related]
35. [Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes]. Wu D; Li X; Chang C; Wu L; Su J; Zhang X; Zhou L; Song L; He Q; Xiao C; Zhang Z; Guo C Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):173-5. PubMed ID: 24606665 [No Abstract] [Full Text] [Related]
36. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352 [TBL] [Abstract][Full Text] [Related]